Shubham Chaudhuri
When the world was desperate for a COVID-19 vaccine, one breakthrough came from a collaboration between the American pharmaceutical company Pfizer and the German firm BioNTech. Their vaccine proved to be 94.5 percent effective in preventing the impacts of COVID-19.
One of the key figures involved in the development of the vaccine was Dr. Onyema Ogbuagu of Yale University, a Nigerian national who had completed his medical training from University of Calabar in Nigeria and had interned at the Ebonyi State University Teaching Hospital, before moving to New York to work at the globally renowned Mount Sinai School of Medicine. “Nigerians contribute to the world in so many ways. Our hats off to Dr. Onyema Ogbuagu at Yale who helped develop a Covid-19 vaccine,” read a statement from the US Embassy in Nigeria.
Can Playing Brain Games Really Keep Your Mind Fit? Brain Experts Set the Record Straight
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Complication Rates After Surgery for BPH: Real-World Data
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
ProSciento Expands Executive Scientific Leadership, Appoints Dr Julio Gutierrez as Vice President of Clinical Research and Clinical Science
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
New data released on Thursday, suggests the one-dose Johnson & Johnson (J&J) jab protects against the new, more contagious Delta variant of Covid-19.
In fact, the jab may be better at fending off infections from the new strain than it was at protecting against South Africa’s previous variants.
The vaccine performed even better against the Delta variant in these laboratory tests than against the Beta Covid-19 strain that was, until recently, the dominant strain of the virus in South Africa.
One of the studies was released as a pre-print but has not yet been peer-reviewed. The other is awaiting publication in a peer-reviewed journal.